Q4 EPS Estimates for Sanara MedTech Reduced by HC Wainwright

Sanara MedTech Inc. (NASDAQ:SMTI) – Stock analysts at HC Wainwright lowered their Q4 2026 earnings per share (EPS) estimates for Sanara MedTech in a report issued on Thursday, April 2nd. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of $0.12 per share for the quarter, down from their prior estimate of $0.19. HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share.

SMTI has been the subject of several other research reports. Zacks Research cut Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. Wall Street Zen downgraded shares of Sanara MedTech from a “buy” rating to a “hold” rating in a report on Sunday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sanara MedTech in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Sanara MedTech has an average rating of “Hold” and an average price target of $36.00.

Sanara MedTech Price Performance

Shares of Sanara MedTech stock opened at $17.24 on Friday. The company has a debt-to-equity ratio of 7.75, a current ratio of 1.80 and a quick ratio of 1.59. Sanara MedTech has a 1-year low of $16.05 and a 1-year high of $35.95. The business’s fifty day moving average price is $19.49 and its two-hundred day moving average price is $23.76. The company has a market capitalization of $158.09 million, a P/E ratio of -4.08 and a beta of 1.10.

Sanara MedTech (NASDAQ:SMTI) last issued its quarterly earnings data on Tuesday, March 24th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.07). Sanara MedTech had a negative return on equity of 20.73% and a negative net margin of 36.42%.The business had revenue of $27.55 million during the quarter, compared to the consensus estimate of $27.90 million.

Hedge Funds Weigh In On Sanara MedTech

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SMTI. Stonebridge Wealth Management LLC acquired a new position in shares of Sanara MedTech during the 2nd quarter valued at $3,397,000. Royal Bank of Canada lifted its holdings in shares of Sanara MedTech by 127.3% in the fourth quarter. Royal Bank of Canada now owns 117,643 shares of the company’s stock valued at $2,747,000 after buying an additional 65,887 shares during the period. Marshall Wace LLP boosted its stake in Sanara MedTech by 144.3% during the second quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock valued at $2,030,000 after buying an additional 42,237 shares in the last quarter. Squarepoint Ops LLC grew its holdings in Sanara MedTech by 343.4% during the third quarter. Squarepoint Ops LLC now owns 31,383 shares of the company’s stock worth $996,000 after acquiring an additional 24,305 shares during the period. Finally, Jane Street Group LLC acquired a new position in Sanara MedTech during the fourth quarter worth about $355,000. 8.10% of the stock is owned by institutional investors.

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.